At Inotek, our focus is defining the future of eye care. We’re dedicated to using medical research and scientific innovation to restore and protect the vision of those suffering from diseases of the eye. With the groundbreaking discovery of trabodenoson, we’re ready to offer a pressure relieving solution for the eye with minimal side effects and no painful injections.
- Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting Read Full Press Release
- Inotek Pharmaceuticals Corporation Announces Publication of Phase 1 Data for Trabodenoson in Healthy Adult Volunteers in the Journal of Ocular Pharmacology and Therapeutics Read Full Press Release
- Inotek Pharmaceuticals Announces the Journal of Ocular Pharmacology and Therapeutics has Published its Phase 2 Data for Trabodenoson in Patients with Glaucoma and Ocular Hypertension Read Full Press Release
- Inotek Pharmaceuticals Phase 3 Development Plhan Conference Call Webcast Visit the Webcast Archive